AstraZeneca’s Dual Listing in New York Boosts Global Reach While Strengthening London’s Financial Future
AstraZeneca’s decision to list in New York while retaining its strong London base signals confidence in the UK economy and
Read More
Factual Version of a Story
AstraZeneca cardiovascular medicines